Questionnaire Survey of Possible Association of Allergic Diseases with Adverse Reactions to SARS-CoV-2 Vaccination

Morimoto, Hiroki; Hayano, Satoshi; Ozawa, Naoya; Ogura, Yasuaki; Usui, Hiroaki; Usami, Takahiro; Ohse, Ayako; Otsuka, Masaki; Murakami, Masahiko; Tokura, Y.

doi:10.3390/vaccines9121421

Cited by 3 publications

(2 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The frequency was similar to that in the placebo group (33.6% and 33.0%, respectively) and was consistent with our results (30.4%) [38]. The higher frequency of adverse reactions in those with allergic diseases was consistent with previous reports on adults [39]. It has been suggested that individuals with allergic diseases, such as asthma, who are potentially susceptible to COVID-19 [8; [25][26][27][28][29], may experience more adverse reactions after BNT162b2 vaccination.…”

Section: Discussionsupporting

confidence: 93%

Time course of adverse reactions after BNT162b2 vaccination in healthy and allergic disease individuals aged 5–11 years: an observational and historical cohort study

Yoshida

Kobashi²,

Shimazu

et al. 2022

Preprint

View full text Add to dashboard Cite

Purpose We aimed to assess whether BNT162b2 vaccination in children meets high safety standards by surveying adverse reactions in healthy and allergic disease individuals aged 5–11 years in Japan throughout seven days following their first and second BNT162b2 vaccination. Methods This was an observational and historical cohort study. The eligibility criteria of study participants included those aged 5–11 years, who received two doses of BNT162b2, with consent by the children and their guardians. We collected data on sex, age, height, weight, blood type, history of BCG vaccination, allergic disease, medication, history of COVID-19 infection and adverse reactions seven days following the first and second BNT162b2 vaccination using a questionnaire. We used previous reports to compare our result with individuals aged 12–15years. Results A total of 421 participants were eligible for this study. Among the 216 patients with allergic disease, 48 (22.2%) had experienced worsening of their chronic diseases, and the frequency of fatigue and dizziness after the second dose was higher than that of healthy individuals. The experience of systemic adverse reactions was associated with asthma. The frequency of headache, diarrhea, fatigue, muscle/joint pain, and fever after the second BNT162b2 vaccination was lower in the individuals aged 5–11 years than in those aged 12–15 years. Fever was the only systemic adverse reaction that lasted longer than five days (1.0% of participants). Conclusions Individuals with allergic diseases, who are potentially susceptible to COVID-19, may experience worsening of their chronic diseases and more frequent adverse reactions after BNT162b2 vaccination than healthy individuals. To ensure that children with allergic diseases receive the vaccine safely, further information needs to be collected.

show abstract

Section: Discussionsupporting

confidence: 93%

Time course of adverse reactions after BNT162b2 vaccination in healthy and allergic disease individuals aged 5–11 years: an observational and historical cohort study

Yoshida

Kobashi²,

Shimazu

et al. 2022

Preprint

View full text Add to dashboard Cite

show abstract

“…The frequency was similar to that in the placebo group (33.6 and 33.0%, respectively) and was consistent with our results (30.4%) [ 39 ]. The higher frequency of adverse reactions in those with allergic diseases was consistent with previous reports on adults [ 40 ]. It has been suggested that individuals with allergic diseases, such as asthma, who are potentially susceptible to COVID-19 [ 8 , 25 – 29 ], may experience more adverse reactions after BNT162b2 vaccination.…”

Section: Discussionsupporting

confidence: 92%

Time course of adverse reactions following BNT162b2 vaccination in healthy and allergic disease individuals aged 5–11 years and comparison with individuals aged 12–15 years: an observational and historical cohort study

et al. 2022

View full text Add to dashboard Cite

We aimed to investigate the type and frequency of adverse events over 7 days following the first and second BNT162b2 vaccination. This observational and historical cohort study included patients aged 5–11 years who received two doses of BNT162b2 and provided consent along with their guardians. We collected data on sex, age, height, weight, blood type, history of Bacille Calmette-Guerin vaccination, allergic disease, medication, history of coronavirus disease 2019 (COVID-19), and adverse reactions 7 days following the first and second BNT162b2 vaccination using a questionnaire. Our results were compared with previously reported results for individuals aged 12–15 years. A total of 421 participants were eligible for this study. Among the 216 patients with allergic disease, 48 (22.2%) had experienced worsening of their chronic diseases, and the frequency of fatigue and dizziness after the second dose was higher than that of healthy individuals. The experience of systemic adverse reactions was associated with asthma. The frequency of headache, diarrhea, fatigue, muscle/joint pain, and fever after the second BNT162b2 vaccination was lower in individuals aged 5–11 years than in those aged 12–15 years. Fever was the only systemic adverse reaction that lasted longer than 5 days (1.0% of participants).Conclusions: Individuals with allergic diseases, who are potentially susceptible to COVID-19, may experience worsening of their chronic diseases and more frequent adverse reactions after BNT162b2 vaccination than healthy individuals. To ensure that children with allergic diseases receive the vaccine safely, further information needs to be collected. What is Known:• Adverse reactions after BNT162b2 vaccination among individuals aged 5–11 years are generally nonserious, more common after second vaccination, and substantially less common compared to those observed among individuals aged 12–15 years. What is New:• Individuals with allergic diseases experienced worsening of their chronic diseases and more frequent adverse reactions after BNT162b2 vaccination than healthy individuals.• Systemic adverse reactions were associated with asthma. Fever was the only systemic adverse reaction that lasted longer than 5 days.

show abstract

Impact of COVID-19 pandemic on adults and children with atopic dermatitis and food allergy: Systematic review

Ne,

Suaini,

Aung

et al. 2024

Journal of Allergy and Clinical Immunology: Global

View full text Add to dashboard Cite

Questionnaire Survey of Possible Association of Allergic Diseases with Adverse Reactions to SARS-CoV-2 Vaccination

Cited by 3 publications

References 20 publications

Time course of adverse reactions after BNT162b2 vaccination in healthy and allergic disease individuals aged 5–11 years: an observational and historical cohort study

Time course of adverse reactions after BNT162b2 vaccination in healthy and allergic disease individuals aged 5–11 years: an observational and historical cohort study

Time course of adverse reactions following BNT162b2 vaccination in healthy and allergic disease individuals aged 5–11 years and comparison with individuals aged 12–15 years: an observational and historical cohort study

Impact of COVID-19 pandemic on adults and children with atopic dermatitis and food allergy: Systematic review

Contact Info

Product

Resources

About